683 Capital Management’s Viridian Therapeutics VRDN Stock Holding History

683 Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,265	Closed	-$338K	–	328
2022 Q1	$338K	Sell	18,265 -3,363	-16%	-$64.6K	0.02%	218
2021 Q4	$428K	Buy	+21,628	New	+$403K	0.02%	218
2020 Q1	–	Sell	-19,333	Closed	-$139K	–	179
2019 Q4	$139K	Sell	19,333 -98,403	-84%	-$1.01M	0.02%	141
2019 Q3	$1.29M	Hold	117,736	–	–	0.14%	75
2019 Q2	$3.62M	Hold	117,736	–	–	0.33%	64
2019 Q1	$4.93M	Buy	117,736 +4,600	+4%	+$208K	0.45%	50
2018 Q4	$5.14M	Buy	+113,136	New	+$6.54M	0.31%	56
2018 Q3	–	Sell	-33,333	Closed	-$3.21M	–	175
2018 Q2	$3.21M	Hold	33,333	–	–	0.22%	67
2018 Q1	$3.5M	Buy	+33,333	New	+$3.62M	0.31%	67

Other funds holding VRDN

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

683 Capital Management's VRDN Position: Q2 2022 in Review

683 Capital Management sold out of Viridian Therapeutics (VRDN) in Q2 2022, closing a stake of 18,265 shares — an estimated $338K sold.

683 Capital Management first reported a position in VRDN in Q1 2018 and held it in 9 quarters. The position peaked at $5.14M in Q4 2018. 84 funds tracked by Wall St. Rank hold VRDN as of Q2 2022.

683 Capital Management reported no remaining Viridian Therapeutics position as of Q2 2022 after selling out during the quarter.
683 Capital Management sold 18,265 Viridian Therapeutics shares in Q2 2022, an estimated $338K.
683 Capital Management first reported a position in Viridian Therapeutics in Q1 2018 and held it in 9 quarters.
683 Capital Management's Viridian Therapeutics position peaked at $5.14M in Q4 2018.
84 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.